Published in Epidemiol Infect on June 01, 2000
Health Risks Associated with Visiting Friends and Relatives in Developing Countries. Curr Infect Dis Rep (2005) 1.09
Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. Eur J Epidemiol (2007) 1.07
Epidemiology and economic burden of viral hepatitis: an observational population based study. Gut (2002) 0.96
Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study. BMC Infect Dis (2007) 0.86
HAV Immunity in Iranian Medical Students. Hepat Mon (2015) 0.81
Effects of an ageing population and the replacement of immune birth cohorts on the burden of hepatitis A in the Netherlands. BMC Infect Dis (2013) 0.81
Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran. J Res Med Sci (2014) 0.80
Changes in the epidemiology of hepatitis A outbreaks 13 years after the introduction of a mass vaccination program. Hum Vaccin Immunother (2014) 0.80
A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium. Eur J Epidemiol (2007) 0.79
Hepatitis A virus immunity and seroconversion among contacts of acute hepatitis A patients in Amsterdam, 1996-2000: an evaluation of current prevention policy. Am J Public Health (2004) 0.77
Socioeconomic correlates of antibody levels to enteric pathogens among Israeli adolescents. Epidemiol Infect (2006) 0.75
Is publication bias a medical problem? Lancet (1993) 3.04
Immunity to poliomyelitis in The Netherlands. Am J Epidemiol (2001) 2.60
Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol (2000) 2.40
Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis (2010) 2.26
[Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk]. Ned Tijdschr Geneeskd (2007) 2.26
Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect (2008) 2.01
Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis (2007) 1.97
Fusobacterium nucleatum septicemia and portal vein thrombosis. Clin Infect Dis (1999) 1.83
Making innovations accessible to the poor through implementation research. Int J Tuberc Lung Dis (2011) 1.75
Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med (2009) 1.60
[Varicella: previously healthy children sometimes develop complications]. Ned Tijdschr Geneeskd (2006) 1.41
Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccine coverage. Vaccine (1999) 1.38
[Vaccines against human papillomavirus (HPV); between registration and implementation]. Ned Tijdschr Geneeskd (2008) 1.34
Measles outbreak in a community with very low vaccine coverage, the Netherlands. Emerg Infect Dis (2001) 1.33
Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiol Infect (2005) 1.28
Simultaneous increase of Cryptosporidium infections in the Netherlands, the United Kingdom and Germany in late summer season, 2012. Euro Surveill (2013) 1.22
Mumps epidemic in orthodox religious low-vaccination communities in the Netherlands and Canada, 2007 to 2009. Euro Surveill (2011) 1.22
Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect (2002) 1.19
Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands. Math Biosci (2000) 1.17
Random effect modelling of patient-related risk factors in orthopaedic procedures: results from the Dutch nosocomial infection surveillance network 'PREZIES'. J Hosp Infect (2006) 1.06
The seroepidemiology of measles in Western Europe. Epidemiol Infect (2001) 1.04
Prevalence of antibodies against rubella virus in The Netherlands 9 years after changing from selective to mass vaccination. Epidemiol Infect (1999) 1.02
Progress towards tuberculosis elimination: secular trend, immigration and transmission. Eur Respir J (2009) 1.01
Poliovirus circulation among schoolchildren during the early phase of the 1992-1993 poliomyelitis outbreak in The Netherlands. J Infect Dis (2001) 0.99
Integration of HIV testing in tuberculosis drug resistance surveillance in Kazakhstan and Kenya. Int J Tuberc Lung Dis (2012) 0.98
Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. Cancer Epidemiol (2012) 0.96
Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003-2005. Eur J Clin Microbiol Infect Dis (2008) 0.95
A model based evaluation of the 1996-7 pertussis epidemic in The Netherlands. Epidemiol Infect (2001) 0.91
Validation of surgical site infection surveillance in the Netherlands. Infect Control Hosp Epidemiol (2006) 0.91
Chlamydia pneumoniae and Mycoplasma pneumoniae in children with acute respiratory infection in general practices in The Netherlands. Scand J Infect Dis (2000) 0.90
Antibiotic use and other risk factors at hospital level for outbreaks with Clostridium difficile PCR ribotype 027. J Med Microbiol (2008) 0.90
Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine (2011) 0.88
[Measles epidemiology in the Netherlands: a exploratory analysis of notification]. Ned Tijdschr Geneeskd (2000) 0.88
Antibodies against mumps in The Netherlands as assessed by indirect ELISA and virus neutralization assay. Epidemiol Infect (2003) 0.87
Performance of Meridian ImmunoCard Mycoplasma Test in a multicenter clinical trial. J Clin Microbiol (1996) 0.87
[Increase in the number of invasive Haemophilus influenzae type b infections]. Ned Tijdschr Geneeskd (2005) 0.87
Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine (2008) 0.87
Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test. Clin Diagn Lab Immunol (1997) 0.86
[Effect of vaccination against pertussis on the incidence of pertussis in The Netherlands, 1996-2003]. Ned Tijdschr Geneeskd (2005) 0.86
Helminths and skewed cytokine profiles increase tuberculin skin test positivity in Warao Amerindians. Tuberculosis (Edinb) (2012) 0.86
Sero-epidemiology of mumps in western Europe. Epidemiol Infect (2003) 0.86
High tetanus antitoxin antibody concentrations in the Netherlands: a seroepidemiological study. Vaccine (2010) 0.85
Laboratory investigations in the diagnosis of septicaemia and malaria. East Afr Med J (1997) 0.85
Comparison of the National Surgical Site Infection surveillance data between The Netherlands and Germany: PREZIES versus KISS. J Hosp Infect (2007) 0.83
How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Vaccine (2009) 0.83
Availability of second-line drugs and anti-tuberculosis drug susceptibility testing in China: a situational analysis. Int J Tuberc Lung Dis (2010) 0.83
Detection of intestinal protozoa in paediatric patients with gastrointestinal symptoms by multiplex real-time PCR. Clin Microbiol Infect (2013) 0.82
A multiplex real-time PCR assay for routine diagnosis of bacterial vaginosis. Eur J Clin Microbiol Infect Dis (2015) 0.81
Incidence of multiple sclerosis in the general population in the Netherlands, 1996-2008. Neuroepidemiology (2012) 0.80
Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands. Eur J Pediatr (2014) 0.79
Drug susceptibility of Mycobacterium tuberculosis in HIV-infected and -uninfected Ethiopians and its impact on outcome after 24 months of follow-up. Int J Tuberc Lung Dis (2004) 0.78
Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands. Vaccine (2012) 0.78
[Influenza season 1999/2000 and vaccine composition for the season 2000/01]. Ned Tijdschr Geneeskd (2000) 0.78
A population-based study on tetanus antitoxin levels in The Netherlands. Vaccine (1999) 0.78
[Influenza season 1998/99; composition of vaccine for 1999/2000]. Ned Tijdschr Geneeskd (1999) 0.78
Antibodies to Haemophilus influenzae serotype b in the Netherlands a few years after the introduction of routine vaccination. Clin Infect Dis (2000) 0.77
Evaluation of the national immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b. Vaccine (2003) 0.77
Impact of transition from microscopy to molecular screening for detection of intestinal protozoa in Dutch patients. Clin Microbiol Infect (2014) 0.77
Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series. Euro Surveill (2014) 0.76
Self-treatment by adults during slow-onset exacerbations of asthma. Patient Educ Couns (1997) 0.76
[Vaccination against mumps successful]. Ned Tijdschr Geneeskd (1993) 0.75
[Rubella epidemic in the Netherlands, 2004/'05: awareness of congenital rubella syndrome required]. Ned Tijdschr Geneeskd (2005) 0.75
[Infection prevention in newborns through maternal vaccination: current insights and developments]. Ned Tijdschr Geneeskd (2016) 0.75
[Influenza A(H5N1): current status]. Tijdschr Diergeneeskd (1998) 0.75
Annual meeting of the Tuberculosis Surveillance and Research Unit, 2008. Int J Tuberc Lung Dis (2009) 0.75
Broader vaccination of expatriates against HBV infection: do we reach those at highest risk? Int J Epidemiol (1999) 0.75
[The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients]. Ned Tijdschr Geneeskd (2003) 0.75
[The influenza season 1997/'98 and the vaccine composition for 1998/'99]. Ned Tijdschr Geneeskd (1998) 0.75